For decades, statins have served as the “go-to” drug for patients with high cholesterol. Now, a new class of cholesterol-reducing drugs, PCSK9 inhibitors, just approved by the FDA, offers a possible alternative to statins. Adding to the changing landscape of cholesterol treatment are recommendations from the American Heart Association and American College of Cardiology, issued in 2013, that dramatically expanded the number of people who could potentially receive statins to prevent heart attack or stroke. Together,these developments have renewed focus on cholesterol as a major health issue. What role might this new class of cholesterol-lowering drugs play? How might their cost impact access and insurance coverage? What lifestyle factors, especially dietary fats, influence the prevention and treatment of cholesterol-related risk factors? Part of The Dr. Lawrence H. and Roberta Cohn Forums, this webcast was presented September 24, 2015 in Collaboration with Reuters and in Association with Harvard Health Publications. Watch the entire series from The Forum at Harvard T.H. Chan School of Public Health at www.ForumHSPH.org.